The development and benefits of metformin in various diseases.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic review methodology or primary data
PubMed 37402952 · doi:10.1007/s11684-023-0998-6
What was done
The authors reviewed published preclinical and clinical evidence regarding metformin, focusing on its pharmacokinetics, mechanisms of action (particularly mitochondrial respiratory-chain complex I inhibition and AMPK activation), treatment strategies, clinical applications, and potential risks across four disease categories: metabolic-associated diseases, cancer, aging and age-related diseases, and neurological disorders.
What was found
The abstract reports no quantitative data, effect sizes, or study metrics. It notes the primary described downstream mechanism of metformin as inhibition of mitochondrial respiratory-chain complex I leading to decreased ATP production and AMPK activation, and identifies ongoing preclinical and clinical efforts to expand metformin use beyond type 2 diabetes.
Why it matters
Given metformin's established safety profile and low cost, summarizing its proposed biological targets across multiple non-diabetic conditions helps frame hypotheses and directions for future translational and longitudinal research.
Limits
This is a narrative review with no described systematic search criteria, quality appraisal, or quantitative data synthesis. The abstract provides no specific study count, sample sizes, or numerical results, and the clinical utility of metformin outside diabetes remains investigational.
Cited by
- supports Metformin activates AMPK by inhibiting ATP production through the mitochondrial respiratory chain.